Get the Stockscreener App
1.07
8.55%
-0.10
Phio Pharmaceuticals Corp stock is traded at $1.07, with a volume of 152.51K.
It is down -8.55% in the last 24 hours and down -18.94% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$1.17
Open:
$1.16
24h Volume:
152.51K
Relative Volume:
0.03
Market Cap:
$5.16M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.1312
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-17.05%
1M Performance:
-18.94%
6M Performance:
-65.26%
1Y Performance:
-82.85%
1-Day Range:
$1.05
$1.16
1-Week Range:
$1.05
$1.32
52-Week Range:
$1.05
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.08 | 5.16M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.11 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
581.55 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.40 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.76 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
240.81 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Groundbreaking Cancer Treatment Data: Phio's Dual Immunotherapy Candidates Show Promise - Stock Titan
Phio stock hits 52-week low at $1.22 amid sharp annual decline - Investing.com
Phio stock hits 52-week low at $1.22 amid sharp annual decline By Investing.com - Investing.com South Africa
Phio Pharmaceuticals Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Virtu Financial LLC Makes New Investment in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update - TradingView
Phio's Cancer Drug Shows Complete Response as Company Slashes Losses by 33% - Stock Titan
Phio Pharmaceuticals (PHIO) Expected to Announce Earnings on Monday - Defense World
PHIO PHARMACEUTICALS CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
PHIOPhio Pharmaceuticals Corp Latest Stock News & Market Updates - Stock Titan
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting - Quantisnow
Phio Reports 50% Complete Response Rate in Skin Cancer Trial - StockTitan
Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study - Newsfile
PHIO stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Australia
Phio Pharma Stock Quadruples On Positive Data From Cancer Treatment Trial: Retail’s Elated - MSN
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Can Phio's Novel siRNA Cancer Technology Impress Investors at Upcoming Roadshow? - StockTitan
PHIO stock touches 52-week low at $1.48 amid market challenges - Investing.com
PHIO stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Brokers Offer Predictions for PHIO FY2024 Earnings - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals Appoints David Deming to Board - TipRanks
Phio Pharmaceuticals expands board with new director By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals Corp. Appoints David H. Deming to Board of Directors -February 20, 2025 at 09:54 am EST - Marketscreener.com
H.C. Wainwright maintains Buy rating, $4 target on Phio Pharma stock - Investing.com
Phio Pharmaceuticals expands board with new director - Investing.com
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors - Newsfile
Phio Pharmaceuticals (NASDAQ:PHIO) Given “Buy” Rating at HC Wainwright - Defense World
PHIO Stock: The Biotech Breakthrough You Can't Ignore! Is This the Future of Immunotherapy? - Elblog.pl
Reviewing BridgeBio Pharma (NASDAQ:BBIO) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals (NASDAQ:PHIO) Shares Down 5.8% – Should You Sell? - Defense World
Phio Pharma (NASDAQ:PHIO) Stock Quotes, Forecast and News Summary - Benzinga
Inside Phio's Revolutionary siRNA Cancer Treatment: CEO Reveals Clinical Progress - StockTitan
Revolutionary Cancer Treatment or Environmental Savior? - Elblog.pl
Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis - MarketBeat
Phio Pharmaceuticals CEO to Present Breakthrough Cancer Treatment at Renmark Virtual Roadshow - StockTitan
Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile
We Asked Retail What's Next For Phio Pharma After Monday's Blistering Rally: Most See More Room To Run - MSN
Phio Pharmaceuticals Raises $1.83M in Direct Offering with Warrant Coverage at $3.00/Share - StockTitan
Stock market news: Phio Pharmaceuticals +50.19%, DatChat +46.01% among top gainers during mid day trading - Business Upturn
Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Financial Content
Biotech Alert: Searches spiking for these stocks today - TipRanks
Stock market today: Phio Pharmaceuticals -20.76%, Soligenix -20.15% among biggest losers in early trading - Business Upturn
Phio Pharmaceuticals Raises $2.5M Through Direct Offering at $3.00 Per Share - StockTitan
Phio Pharmaceuticals sharply lower on equity offering - MSN
Stock market news: PTL -68.18%, Springview Holdings -41.63% among biggest losers during mid day trading - Business Upturn
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | President & CEO |
Jun 06 '24 |
Buy |
0.75 |
1,000 |
750 |
19,990 |
2.65%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):